{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:32:01Z","timestamp":1770823921976,"version":"3.50.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s00428-008-0665-y","type":"journal-article","created":{"date-parts":[[2008,9,17]],"date-time":"2008-09-17T06:45:14Z","timestamp":1221633914000},"page":"417-431","source":"Crossref","is-referenced-by-count":229,"title":["KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program"],"prefix":"10.1007","volume":"453","author":[{"given":"J. H. J. M.","family":"van Krieken","sequence":"first","affiliation":[]},{"given":"A.","family":"Jung","sequence":"additional","affiliation":[]},{"given":"T.","family":"Kirchner","sequence":"additional","affiliation":[]},{"given":"F.","family":"Carneiro","sequence":"additional","affiliation":[]},{"given":"R.","family":"Seruca","sequence":"additional","affiliation":[]},{"given":"F. T.","family":"Bosman","sequence":"additional","affiliation":[]},{"given":"P.","family":"Quirke","sequence":"additional","affiliation":[]},{"given":"J. F.","family":"Fl\u00e9jou","sequence":"additional","affiliation":[]},{"given":"T.","family":"Plato Hansen","sequence":"additional","affiliation":[]},{"given":"G.","family":"de Hertogh","sequence":"additional","affiliation":[]},{"given":"P.","family":"Jares","sequence":"additional","affiliation":[]},{"given":"C.","family":"Langner","sequence":"additional","affiliation":[]},{"given":"G.","family":"Hoefler","sequence":"additional","affiliation":[]},{"given":"M.","family":"Ligtenberg","sequence":"additional","affiliation":[]},{"given":"D.","family":"Tiniakos","sequence":"additional","affiliation":[]},{"given":"S.","family":"Tejpar","sequence":"additional","affiliation":[]},{"given":"G.","family":"Bevilacqua","sequence":"additional","affiliation":[]},{"given":"A.","family":"Ensari","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2008,9,18]]},"reference":[{"key":"665_CR1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3816\/CBC.2004.n.011","volume":"5","author":"MA Owens","year":"2004","unstructured":"Owens MA, Horten BC, Da Silva MM (2004) HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6,556 breast cancer tissues. Clin Breast Cancer 5:63\u201369","journal-title":"Clin Breast Cancer"},{"key":"665_CR2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/modpathol.3800774","volume":"20","author":"M Dowsett","year":"2007","unstructured":"Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Ruschoff J, Gutjahr T, Habben K, van de Vijver MJ (2007) Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod Pathol 20:584\u2013591","journal-title":"Mod Pathol"},{"key":"665_CR3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van d V, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118\u2013145","journal-title":"J Clin Oncol"},{"key":"665_CR4","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/jcp.2004.025551","volume":"59","author":"IO Ellis","year":"2006","unstructured":"Ellis IO, Coleman D, Wells C, Kodikara S, Paish EM, Moss S, Al-Sam S, Anderson N, Bobrow L, Buley I, Connolly CE, Dallimore NS, Hales S, Hanby A, Humphreys S, Knox F, Lowe J, Macartney J, Nash R, Parham D, Patnick J, Pinder SE, Quinn CM, Robertson AJ, Shrimankar J, Walker RA, Winder R (2006) Impact of a national external quality assessment scheme for breast pathology in the UK. J Clin Pathol 59:138\u2013145","journal-title":"J Clin Pathol"},{"key":"665_CR5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71\u201396","journal-title":"CA Cancer J Clin"},{"key":"665_CR6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/jso.2930510304","volume":"51","author":"AW Hemming","year":"1992","unstructured":"Hemming AW, Davis NL, Kluftinger A, Robinson B, Quenville NF, Liseman B, LeRiche J (1992) Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol 51:147\u2013152","journal-title":"J Surg Oncol"},{"key":"665_CR7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0960-7404(92)90062-P","volume":"1","author":"AM Kluftinger","year":"1992","unstructured":"Kluftinger AM, Robinson BW, Quenville NF, Finley RJ, Davis NL (1992) Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol 1:97\u2013105","journal-title":"Surg Oncol"},{"key":"665_CR8","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1002\/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2","volume":"71","author":"A Mayer","year":"1993","unstructured":"Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H (1993) The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71:2454\u20132460","journal-title":"Cancer"},{"key":"665_CR9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","volume":"19","author":"DS Salomon","year":"1995","unstructured":"Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183\u2013232","journal-title":"Crit Rev Oncol Hematol"},{"key":"665_CR10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/annonc\/mdi006","volume":"16","author":"JP Spano","year":"2005","unstructured":"Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, Attar A, Benichou J, Martin A, Morere JF, Raphael M, Penault-Llorca F, Breau JL, Fagard R, Khayat D, Wind P (2005) Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16:102\u2013108","journal-title":"Ann Oncol"},{"key":"665_CR11","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","volume":"22","author":"LB Saltz","year":"2004","unstructured":"Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201\u20131208","journal-title":"J Clin Oncol"},{"key":"665_CR12","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","volume":"358","author":"F Ciardiello","year":"2008","unstructured":"Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160\u20131174","journal-title":"N Engl J Med"},{"key":"665_CR13","doi-asserted-by":"crossref","first-page":"ii42","DOI":"10.1093\/annonc\/mdj920","volume":"2","author":"G Metro","year":"2006","unstructured":"Metro G, Finocchiaro G, Cappuzzo F (2006) Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. Ann Oncol 17 Suppl 2:ii42\u2013ii45","journal-title":"Ann Oncol 17 Suppl"},{"key":"665_CR14","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1200\/JCO.2007.11.8984","volume":"25","author":"PM Harari","year":"2007","unstructured":"Harari PM, Allen GW, Bonner JA (2007) Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 25:4057\u20134065","journal-title":"J Clin Oncol"},{"key":"665_CR15","doi-asserted-by":"crossref","first-page":"7242","DOI":"10.1158\/1078-0432.CCR-06-0646","volume":"12","author":"M Ono","year":"2006","unstructured":"Ono M, Kuwano M (2006) Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 12:7242\u20137251","journal-title":"Clin Cancer Res"},{"key":"665_CR16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.seminoncol.2004.09.036","volume":"32","author":"AC Lockhart","year":"2005","unstructured":"Lockhart AC, Berlin JD (2005) The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol 32:52\u201360","journal-title":"Semin Oncol"},{"key":"665_CR17","first-page":"1159","volume":"29","author":"KL Spindler","year":"2006","unstructured":"Spindler KL, Lindebjerg J, Nielsen JN, Olsen DA, Bisgard C, Brandslund I, Jakobsen A (2006) Epidermal growth factor receptor analyses in colorectal cancer: a comparison of methods. Int J Oncol 29:1159\u20131165","journal-title":"Int J Oncol"},{"key":"665_CR18","doi-asserted-by":"crossref","first-page":"s4606","DOI":"10.1158\/1078-0432.CCR-07-0332","volume":"13","author":"PD Bonomi","year":"2007","unstructured":"Bonomi PD, Buckingham L, Coon J (2007) Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res 13:s4606\u2013s4612","journal-title":"Clin Cancer Res"},{"key":"665_CR19","doi-asserted-by":"crossref","first-page":"6650","DOI":"10.1158\/1078-0432.CCR-05-0738","volume":"11","author":"S Ogino","year":"2005","unstructured":"Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, Kulke MH, Ryan DP, Loda M, Fuchs CS (2005) Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 11:6650\u20136656","journal-title":"Clin Cancer Res"},{"key":"665_CR20","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497\u20131500","journal-title":"Science"},{"key":"665_CR21","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","volume":"101","author":"W Pao","year":"2004","unstructured":"Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H (2004) EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306\u201313311","journal-title":"Proc Natl Acad Sci U S A"},{"key":"665_CR22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/107327480701400313","volume":"14","author":"CM Rocha-Lima","year":"2007","unstructured":"Rocha-Lima CM, Soares HP, Raez LE, Singal R (2007) EGFR targeting of solid tumors. Cancer Control 14:295\u2013304","journal-title":"Cancer Control"},{"key":"665_CR23","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van HG, Wierzbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040\u20132048","journal-title":"N Engl J Med"},{"key":"665_CR24","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","volume":"26","author":"RG Amado","year":"2008","unstructured":"Amado RG, Wolf M, Peeters M, Van CE, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626\u20131634","journal-title":"J Clin Oncol"},{"key":"665_CR25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van CE (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337\u2013345","journal-title":"N Engl J Med"},{"key":"665_CR26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3816\/CCC.2006.n.01","volume":"6","author":"TB Gibson","year":"2006","unstructured":"Gibson TB, Ranganathan A, Grothey A (2006) Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 6:29\u201331","journal-title":"Clin Colorectal Cancer"},{"key":"665_CR27","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/sj.bjc.6604053","volume":"97","author":"S Siena","year":"2007","unstructured":"Siena S, Peeters M, Van CE, Humblet Y, Conte P, Bajetta E, Comandini D, Bodoky G, van HG, Salek T, Wolf M, Devercelli G, Woolley M, Amado RG (2007) Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer 97:1469\u20131474","journal-title":"Br J Cancer"},{"key":"665_CR28","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"CE Van","year":"2007","unstructured":"Van CE, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658\u20131664","journal-title":"J Clin Oncol"},{"key":"665_CR29","first-page":"19","volume":"1","author":"R Radinsky","year":"1995","unstructured":"Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, Bucana CD, Fidler IJ (1995) Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1:19\u201331","journal-title":"Clin Cancer Res"},{"key":"665_CR30","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/bjs.1800771211","volume":"77","author":"RJ Steele","year":"1990","unstructured":"Steele RJ, Kelly P, Ellul B, Eremin O (1990) Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 77:1352\u20131354","journal-title":"Br J Surg"},{"key":"665_CR31","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0360-3016(02)03752-5","volume":"54","author":"J Giralt","year":"2002","unstructured":"Giralt J, Eraso A, Armengol M, Rossello J, Majo J, Ares C, Espin E, Benavente S, de T I (2002) Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 54:1460\u20131465","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"665_CR32","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2005.08.037","volume":"23","author":"KY Chung","year":"2005","unstructured":"Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803\u20131810","journal-title":"J Clin Oncol"},{"key":"665_CR33","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(05)70102-9","volume":"6","author":"M Moroni","year":"2005","unstructured":"Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di NF, Gambacorta M, Siena S, Bardelli A (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279\u2013286","journal-title":"Lancet Oncol"},{"key":"665_CR34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1245\/s10434-007-9667-2","volume":"15","author":"A Italiano","year":"2008","unstructured":"Italiano A, Follana P, Caroli FX, Badetti JL, Benchimol D, Garnier G, Gugenheim J, Haudebourg J, Keslair F, Lesbats G, Lledo G, Roussel JF, Pedeutour F, Francois E (2008) Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann Surg Oncol 15:649\u2013654","journal-title":"Ann Surg Oncol"},{"key":"665_CR35","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/annonc\/mdl037","volume":"17","author":"M Francoual","year":"2006","unstructured":"Francoual M, Etienne-Grimaldi MC, Formento JL, Benchimol D, Bourgeon A, Chazal M, Letoublon C, Andre T, Gilly N, Delpero JR, Lasser P, Spano JP, Milano G (2006) EGFR in colorectal cancer: more than a simple receptor. Ann Oncol 17:962\u2013967","journal-title":"Ann Oncol"},{"key":"665_CR36","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/jnci\/dji112","volume":"97","author":"F Cappuzzo","year":"2005","unstructured":"Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643\u2013655","journal-title":"J Natl Cancer Inst"},{"key":"665_CR37","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.humpath.2007.10.027","volume":"39","author":"N Hijiya","year":"2008","unstructured":"Hijiya N, Miyawaki M, Kawahara K, Akamine S, Tsuji K, Kadota J, Akizuki S, Uchida T, Matsuura K, Tsukamoto Y, Moriyama M (2008) Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma. Hum Pathol 39:316\u2013323","journal-title":"Hum Pathol"},{"key":"665_CR38","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/ijc.23388","volume":"122","author":"L Barault","year":"2008","unstructured":"Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, Lievre A, Cortet M, Bouvier AM, Rat P, Roignot P, Faivre J, Laurent-Puig P, Piard F (2008) Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 122:2255\u20132259","journal-title":"Int J Cancer"},{"key":"665_CR39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/00313020801911512","volume":"40","author":"YH Tan","year":"2008","unstructured":"Tan YH, Liu Y, Eu KW, Ang PW, Li WQ, Salto-Tellez M, Iacopetta B, Soong R (2008) Detection of BRAF V600E mutation by pyrosequencing. Pathology 40:295\u2013298","journal-title":"Pathology"},{"key":"665_CR40","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/jcp.20310","volume":"204","author":"D Calistri","year":"2005","unstructured":"Calistri D, Rengucci C, Seymour I, Lattuneddu A, Polifemo AM, Monti F, Saragoni L, Amadori D (2005) Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Physiol 204:484\u2013488","journal-title":"J Cell Physiol"},{"key":"665_CR41","doi-asserted-by":"crossref","first-page":"9192","DOI":"10.1038\/sj.onc.1207061","volume":"22","author":"C Oliveira","year":"2003","unstructured":"Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E, Espin E, Armengol M, Yamamoto H, Hamelin R, Seruca R, Schwartz S Jr (2003) BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 22:9192\u20139196","journal-title":"Oncogene"},{"key":"665_CR42","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/gcc.10310","volume":"39","author":"E Domingo","year":"2004","unstructured":"Domingo E, Espin E, Armengol M, Oliveira C, Pinto M, Duval A, Brennetot C, Seruca R, Hamelin R, Yamamoto H, Schwartz S Jr (2004) Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer 39:138\u2013142","journal-title":"Genes Chromosomes Cancer"},{"key":"665_CR43","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/gut.2005.082933","volume":"55","author":"S Ogino","year":"2006","unstructured":"Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner GJ, Weisenberger DJ, Campan M, Laird PW, Loda M, Fuchs CS (2006) CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 55:1000\u20131006","journal-title":"Gut"},{"key":"665_CR44","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/418934a","volume":"418","author":"H Rajagopalan","year":"2002","unstructured":"Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2002) Tumorigenesis: RAF\/RAS oncogenes and mismatch-repair status. Nature 418:934","journal-title":"Nature"},{"key":"665_CR45","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/path.2295","volume":"214","author":"A Preto","year":"2008","unstructured":"Preto A, Figueiredo J, Velho S, Ribeiro AS, Soares P, Oliveira C, Seruca R (2008) BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. J Pathol 214:320\u2013327","journal-title":"J Pathol"},{"key":"665_CR46","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1158\/0008-5472.CAN-07-5659","volume":"68","author":"M Jhawer","year":"2008","unstructured":"Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Soler RP, Mariadason JM (2008) PIK3CA mutation\/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68:1953\u20131961","journal-title":"Cancer Res"},{"key":"665_CR47","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jnci\/dji174","volume":"97","author":"WL Ince","year":"2005","unstructured":"Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H (2005) Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 97:981\u2013989","journal-title":"J Natl Cancer Inst"},{"key":"665_CR48","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","volume":"66","author":"A Lievre","year":"2006","unstructured":"Lievre A, Bachet JB, Le CD, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992\u20133995","journal-title":"Cancer Res"},{"key":"665_CR49","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.ejca.2005.04.022","volume":"41","author":"S Velho","year":"2005","unstructured":"Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, Schwartz S Jr, Duval A, Carneiro F, Machado JC, Hamelin R, Seruca R (2005) The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 41:1649\u20131654","journal-title":"Eur J Cancer"},{"key":"665_CR50","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/sj.bjc.6604009","volume":"97","author":"M Frattini","year":"2007","unstructured":"Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97:1139\u20131145","journal-title":"Br J Cancer"},{"key":"665_CR51","doi-asserted-by":"crossref","first-page":"928","DOI":"10.4161\/cbt.5.8.3251","volume":"5","author":"S Edkins","year":"2006","unstructured":"Edkins S, O\u2019Meara S, Parker A, Stevens C, Reis M, Jones S, Greenman C, Davies H, Dalgliesh G, Forbes S, Hunter C, Smith R, Stephens P, Goldstraw P, Nicholson A, Chan TL, Velculescu VE, Yuen ST, Leung SY, Stratton MR, Futreal PA (2006) Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 5:928\u2013932","journal-title":"Cancer Biol Ther"},{"key":"665_CR52","doi-asserted-by":"crossref","first-page":"8919","DOI":"10.1158\/0008-5472.CAN-04-2818","volume":"64","author":"T Kosaka","year":"2004","unstructured":"Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64:8919\u20138923","journal-title":"Cancer Res"},{"key":"665_CR53","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1093\/hmg\/ddh238","volume":"13","author":"C Oliveira","year":"2004","unstructured":"Oliveira C, Westra JL, Arango D, Ollikainen M, Domingo E, Ferreira A, Velho S, Niessen R, Lagerstedt K, Alhopuro P, Laiho P, Veiga I, Teixeira MR, Ligtenberg M, Kleibeuker JH, Sijmons RH, Plukker JT, Imai K, Lage P, Hamelin R, Albuquerque C, Schwartz S Jr, Lindblom A, Peltomaki P, Yamamoto H, Aaltonen LA, Seruca R, Hofstra RM (2004) Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 13:2303\u20132311","journal-title":"Hum Mol Genet"},{"key":"665_CR54","doi-asserted-by":"crossref","first-page":"iv44","DOI":"10.1093\/annonc\/mdi907","volume":"4","author":"A Russo","year":"2005","unstructured":"Russo A, Bazan V, Agnese V, Rodolico V, Gebbia N (2005) Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol 16 Suppl 4:iv44\u2013iv49","journal-title":"Ann Oncol 16 Suppl"},{"key":"665_CR55","first-page":"1193","volume":"9","author":"WS Samowitz","year":"2000","unstructured":"Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML (2000) Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 9:1193\u20131197","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"665_CR56","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1054\/bjoc.2001.1964","volume":"85","author":"HJ Andreyev","year":"2001","unstructured":"Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O\u2019Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lovig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urosevic N (2001) Kirsten ras mutations in patients with colorectal cancer: the \u2018RASCAL II\u2019 study. Br J Cancer 85:692\u2013696","journal-title":"Br J Cancer"},{"key":"665_CR57","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00280-007-0644-z","volume":"62","author":"LK Zerbe","year":"2008","unstructured":"Zerbe LK, Dwyer-Nield LD, Fritz JM, Redente EF, Shroyer RJ, Conklin E, Kane S, Tucker C, Eckhardt SG, Gustafson DL, Iwata KK, Malkinson AM (2008) Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. Cancer Chemother Pharmacol 62:605\u2013620","journal-title":"Cancer Chemother Pharmacol"},{"key":"665_CR58","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/jcp.20898","volume":"210","author":"JW Keller","year":"2007","unstructured":"Keller JW, Franklin JL, Graves-Deal R, Friedman DB, Whitwell CW, Coffey RJ (2007) Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium. J Cell Physiol 210:740\u2013749","journal-title":"J Cell Physiol"},{"key":"665_CR59","first-page":"1245","volume":"16","author":"JY Wang","year":"2006","unstructured":"Wang JY, Wang YH, Jao SW, Lu CY, Kuo CH, Hu HM, Hsieh JS, Chong IW, Cheng TL, Lin SR (2006) Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-ras oncogene. Oncol Rep 16:1245\u20131252","journal-title":"Oncol Rep"},{"key":"665_CR60","first-page":"115","volume":"1756","author":"P Castagnola","year":"2005","unstructured":"Castagnola P, Giaretti W (2005) Mutant KRAS, chromosomal instability and prognosis in colorectal cancer. Biochim Biophys Acta 1756:115\u2013125","journal-title":"Biochim Biophys Acta"},{"key":"665_CR61","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/0008-5472.CAN-06-4158","volume":"67","author":"S Benvenuti","year":"2007","unstructured":"Benvenuti S, Sartore-Bianchi A, Di NF, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A (2007) Oncogenic activation of the RAS\/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643\u20132648","journal-title":"Cancer Res"},{"key":"665_CR62","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdm496","volume":"19","author":"RW De","year":"2008","unstructured":"De RW, Piessevaux H, De SJ, Janssens M, De HG, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van CE, Tejpar S (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508\u2013515","journal-title":"Ann Oncol"},{"key":"665_CR63","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6603685","volume":"96","author":"FF Di","year":"2007","unstructured":"Di FF, Blanchard F, Charbonnier F, Le PF, Lamy A, Galais MP, Bastit L, Killian A, Sesboue R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96:1166\u20131169","journal-title":"Br J Cancer"},{"key":"665_CR64","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1200\/JCO.2006.10.5437","volume":"25","author":"S Khambata-Ford","year":"2007","unstructured":"Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA III, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230\u20133237","journal-title":"J Clin Oncol"},{"key":"665_CR65","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1200\/JCO.2007.12.5906","volume":"26","author":"A Lievre","year":"2008","unstructured":"Lievre A, Bachet JB, Boige V, Cayre A, Le CD, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374\u2013379","journal-title":"J Clin Oncol"},{"key":"665_CR66","unstructured":"Juan T, Suggs S, Wolf M, Sarosi I, Freeman D, Oliner K, Bakkar A, Patterson SD (2008) A comparability study of 4 commercial KRAS tests. American Association for Cancer Research (AACR) Annual Meeting, April 12\u201316, 2008, Abstract #1811"},{"key":"665_CR67","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0959-8049(97)10111-3","volume":"34","author":"U Kressner","year":"1998","unstructured":"Kressner U, Bjorheim J, Westring S, Wahlberg SS, Pahlman L, Glimelius B, Lindmark G, Lindblom A, Borresen-Dale AL (1998) Ki-ras mutations and prognosis in colorectal cancer. Eur J Cancer 34:518\u2013521","journal-title":"Eur J Cancer"},{"key":"665_CR68","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/1098-2264(2000)9999:9999<::AID-GCC1037>3.0.CO;2-F","volume":"29","author":"VM Hayes","year":"2000","unstructured":"Hayes VM, Westra JL, Verlind E, Bleeker W, Plukker JT, Hofstra RM, Buys CH (2000) New comprehensive denaturing-gradient-gel-electrophoresis assay for KRAS mutation detection applied to paraffin-embedded tumours. Genes Chromosomes Cancer 29:309\u2013314","journal-title":"Genes Chromosomes Cancer"},{"key":"665_CR69","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/bmc.353","volume":"18","author":"C Zhao","year":"2004","unstructured":"Zhao C, Xu G, Shi X, Ma J, Lu S, Yang Q (2004) Detection of K-ras exon 1 mutations by constant denaturant capillary electrophoresis. Biomed Chromatogr 18:538\u2013541","journal-title":"Biomed Chromatogr"},{"key":"665_CR70","first-page":"586","volume":"15","author":"P Chaubert","year":"1993","unstructured":"Chaubert P, Bautista D, Benhattar J (1993) An improved method for rapid screening of DNA mutations by nonradioactive single-strand conformation polymorphism procedure. Biotechniques 15:586","journal-title":"Biotechniques"},{"key":"665_CR71","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.onc.1202291","volume":"18","author":"M Khanna","year":"1999","unstructured":"Khanna M, Park P, Zirvi M, Cao W, Picon A, Day J, Paty P, Barany F (1999) Multiplex PCR\/LDR for detection of K-ras mutations in primary colon tumors. Oncogene 18:27\u201338","journal-title":"Oncogene"},{"key":"665_CR72","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1525-1578(10)60571-5","volume":"7","author":"S Ogino","year":"2005","unstructured":"Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS (2005) Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 7:413\u2013421","journal-title":"J Mol Diagn"},{"key":"665_CR73","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.prp.2007.06.001","volume":"203","author":"A Poehlmann","year":"2007","unstructured":"Poehlmann A, Kuester D, Meyer F, Lippert H, Roessner A, Schneider-Stock R (2007) K-ras mutation detection in colorectal cancer using the pyrosequencing technique. Pathol Res Pract 203:489\u2013497","journal-title":"Pathol Res Pract"},{"key":"665_CR74","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/bjc.1998.212","volume":"77","author":"JC Fox","year":"1998","unstructured":"Fox JC, England J, White P, Ellison G, Callaghan K, Charlesworth NR, Hehir J, McCarthy TL, Smith-Ravin J, Talbot IC, Snary D, Northover JM, Newton CR, Little S (1998) The detection of K-ras mutations in colorectal cancer using the amplification-refractory mutation system. Br J Cancer 77:1267\u20131274","journal-title":"Br J Cancer"},{"key":"665_CR75","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1136\/jcp.2004.022707","volume":"58","author":"NT Heek van","year":"2005","unstructured":"van Heek NT, Clayton SJ, Sturm PD, Walker J, Gouma DJ, Noorduyn LA, Offerhaus GJ, Fox JC (2005) Comparison of the novel quantitative ARMS assay and an enriched PCR-ASO assay for K-ras mutations with conventional cytology on endobiliary brush cytology from 312 consecutive extrahepatic biliary stenoses. J Clin Pathol 58:1315\u20131320","journal-title":"J Clin Pathol"},{"key":"665_CR76","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2217\/14622416.9.4.463","volume":"9","author":"J Cross","year":"2008","unstructured":"Cross J (2008) DxS Ltd. Pharmacogenomics 9:463\u2013467","journal-title":"Pharmacogenomics"},{"key":"665_CR77","first-page":"5","volume":"16","author":"F Mixich","year":"2007","unstructured":"Mixich F, Ioana M, Voinea F, Saftoiu A, Ciurea T (2007) Noninvasive detection through REMS-PCR technique of K-ras mutations in stool DNA of patients with colorectal cancer. J Gastrointestin Liver Dis 16:5\u201310","journal-title":"J Gastrointestin Liver Dis"},{"key":"665_CR78","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1093\/nar\/gkm809","volume":"35","author":"G Amicarelli","year":"2007","unstructured":"Amicarelli G, Shehi E, Makrigiorgos GM, Adlerstein D (2007) FLAG assay as a novel method for real-time signal generation during PCR: application to detection and genotyping of KRAS codon 12 mutations. Nucleic Acids Res 35:e131","journal-title":"Nucleic Acids Res"},{"key":"665_CR79","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/147323000703500403","volume":"35","author":"K Kimura","year":"2007","unstructured":"Kimura K, Nagasaka T, Hoshizima N, Sasamoto H, Notohara K, Takeda M, Kominami K, Iishii T, Tanaka N, Matsubara N (2007) No duplicate KRAS mutation is identified on the same allele in gastric or colorectal cancer cells with multiple KRAS mutations. J Int Med Res 35:450\u2013457","journal-title":"J Int Med Res"},{"key":"665_CR80","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1039\/b700071e","volume":"132","author":"M Hashimoto","year":"2007","unstructured":"Hashimoto M, Barany F, Xu F, Soper SA (2007) Serial processing of biological reactions using flow-through microfluidic devices: coupled PCR\/LDR for the detection of low-abundant DNA point mutations. Analyst 132:913\u2013921","journal-title":"Analyst"},{"key":"665_CR81","doi-asserted-by":"crossref","first-page":"6937","DOI":"10.1021\/ja034716g","volume":"125","author":"MB Wabuyele","year":"2003","unstructured":"Wabuyele MB, Farquar H, Stryjewski W, Hammer RP, Soper SA, Cheng YW, Barany F (2003) Approaching real-time molecular diagnostics: single-pair fluorescence resonance energy transfer (spFRET) detection for the analysis of low abundant point mutations in K-ras oncogenes. J Am Chem Soc 125:6937\u20136945","journal-title":"J Am Chem Soc"},{"key":"665_CR82","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1021\/ac701702t","volume":"79","author":"J Li","year":"2007","unstructured":"Li J, Zhong W (2007) Typing of multiple single-nucleotide polymorphisms by a microsphere-based rolling circle amplification assay. Anal Chem 79:9030\u20139038","journal-title":"Anal Chem"},{"key":"665_CR83","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.bios.2007.12.011","volume":"23","author":"P Zhang","year":"2008","unstructured":"Zhang P, Chu X, Xu X, Shen G, Yu R (2008) Electrochemical detection of point mutation based on surface ligation reaction and biometallization. Biosens Bioelectron 23:1435\u20131441","journal-title":"Biosens Bioelectron"},{"key":"665_CR84","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/cncr.21558","volume":"106","author":"S Syngal","year":"2006","unstructured":"Syngal S, Stoffel E, Chung D, Willett C, Schoetz D, Schroy P, Jagadeesh D, Morel K, Ross M (2006) Detection of stool DNA mutations before and after treatment of colorectal neoplasia. Cancer 106:277\u2013283","journal-title":"Cancer"}],"updated-by":[{"DOI":"10.1007\/s00428-008-0712-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2009,1,9]],"date-time":"2009-01-09T00:00:00Z","timestamp":1231459200000}}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-008-0665-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T09:48:29Z","timestamp":1550137709000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00428-008-0665-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,18]]},"references-count":84,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["665"],"URL":"https:\/\/doi.org\/10.1007\/s00428-008-0665-y","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00428-008-0712-8","asserted-by":"object"}]},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,18]]}}}